Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

Provincial health officials recommend that Nova Scotians 65 years and older get a dose of Covid-19 vaccine this spring. The ...

COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring “razor ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

The data showed that both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

Novavax (NVAX) stock jumped on Wednesday after the vaccine maker released results from a Phase 3 clinical trial of its COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine. The initial ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

WASHINGTON >> U.S. Health Secretary Robert Kennedy Jr. named eight members to serve on a key panel of vaccine advisers on ...